| Recurrent SMARCA4 mutations in small cell carcinoma of the ovary P Jelinic, JJ Mueller, N Olvera, F Dao, SN Scott, R Shah, JJ Gao, ... Nature genetics 46 (5), 424-426, 2014 | 346 | 2014 |
| Loss of imprinting and cancer P Jelinic, P Shaw The Journal of Pathology: A Journal of the Pathological Society of Great …, 2007 | 294 | 2007 |
| The Testis-Specific Factor CTCFL Cooperates with the Protein Methyltransferase PRMT7 in H19 Imprinting Control Region Methylation P Jelinic, JC Stehle, P Shaw PLoS biology 4 (11), e355, 2006 | 266 | 2006 |
| Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade P Jelinic, J Ricca, E Van Oudenhove, N Olvera, T Merghoub, DA Levine, ... JNCI: Journal of the National Cancer Institute 110 (7), 787-790, 2018 | 147 | 2018 |
| CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary Y Xue, B Meehan, E Macdonald, S Venneti, XQD Wang, L Witkowski, ... Nature communications 10 (1), 558, 2019 | 111 | 2019 |
| Loss of SMARCA4 expression is both sensitive and specific for the diagnosis of small cell carcinoma of ovary, hypercalcemic type N Conlon, A Silva, E Guerra, P Jelinic, BA Schlappe, N Olvera, JJ Mueller, ... The American journal of surgical pathology 40 (3), 395-403, 2016 | 101 | 2016 |
| New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair P Jelinic, DA Levine Molecular cancer therapeutics 13 (6), 1645-1654, 2014 | 96 | 2014 |
| A novel mammalian complex containing Sin3B mitigates histone acetylation and RNA polymerase II progression within transcribed loci P Jelinic, J Pellegrino, G David Molecular and cellular biology 31 (1), 54-62, 2011 | 93 | 2011 |
| Homologous recombination deficiency: concepts, definitions, and assays MD Stewart, D Merino Vega, RC Arend, JF Baden, O Barbash, ... The oncologist 27 (3), 167-174, 2022 | 84 | 2022 |
| Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type P Jelinic, BA Schlappe, N Conlon, J Tseng, N Olvera, F Dao, JJ Mueller, ... Modern Pathology 29 (1), 60-66, 2016 | 75 | 2016 |
| Sin3B expression is required for cellular senescence and is up-regulated upon oncogenic stress KB Grandinetti, P Jelinic, T DiMauro, J Pellegrino, ... Cancer research 69 (16), 6430-6437, 2009 | 58 | 2009 |
| Small cell cancers of the female genital tract: Molecular and clinical aspects JR Patibandla, JE Fehniger, DA Levine, P Jelinic Gynecologic Oncology 149 (2), 420-427, 2018 | 57 | 2018 |
| Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast … EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... Journal of Clinical Oncology 38 (15_suppl), 1013-1013, 2020 | 56 | 2020 |
| Validated gene targets associated with curatively treated advanced serous ovarian carcinoma JN Barlin, P Jelinic, N Olvera, F Bogomolniy, M Bisogna, F Dao, ... Gynecologic oncology 128 (3), 512-517, 2013 | 51 | 2013 |
| Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers HU Osmanbeyoglu, F Shimizu, A Rynne-Vidal, D Alonso-Curbelo, ... Nature communications 10 (1), 4369, 2019 | 27 | 2019 |
| miR-200c-driven mesenchymal-to-epithelial transition is a therapeutic target in uterine carcinosarcomas JH Tseng, M Bisogna, LN Hoang, N Olvera, C Rodriguez-Aguayo, ... Scientific reports 7 (1), 3614, 2017 | 25 | 2017 |
| The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair P Jelinic, LA Eccles, J Tseng, P Cybulska, M Wielgos, SN Powell, ... Oncotarget 8 (8), 13792, 2017 | 17 | 2017 |
| Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis S Loi, R Salgado, P Schmid, J Cortes, DW Cescon, EP Winer, ... JCO precision oncology 7, e2200317, 2023 | 11 | 2023 |
| Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from … S Loi, P Schmid, J Cortes, DW Cescon, EP Winer, DL Toppmeyer, ... Cancer Research 81 (4_Supplement), PD14-07-PD14-07, 2021 | 8 | 2021 |
| 843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100 JA Ledermann, R Shapira-Frommer, AD Santin, A Lisyanskaya, S Pignata, ... Annals of Oncology 31, S631-S632, 2020 | 4 | 2020 |
